Klin Padiatr 2020; 232(02): 97
DOI: 10.1055/s-0040-1701862
PW I-V
Guided Poster Walk
© Georg Thieme Verlag KG Stuttgart · New York

Clinical trial of Childhood, Adolescent and Young Adult Hodgkin Lymphoma in Japan

M Kamei
1   Department of Neonatology and Pediatrics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
,
Y Koga
2   Department of Pediatric Medicine for Hospital Collaboration, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
,
R Fukano
3   Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan
,
M Sekimizu
4   Department of Pediatrics, Nagoya Medical Center, Nagoya, Japan
,
K Ohki
5   Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan
,
T Mori
6   Department of Pediatrics, Kobe University, Kobe, Japan
,
T Osumi
7   National Center for Child Health and Development, Children’s Cancer Center, Tokyo, Japan
,
A Nakazawa
8   Department of Clinical Research, Saitama Children’s Medical Center, Saitama, Japan
,
M Tanaka
9   Department of apediatrics, Fujita Health Univesity, Nagoya, Japan
,
J Ueyama
10   Department of Pediatric, Tottori University Hospital, Yonago, Japan
,
T Tsuchimochi
11   Department of Pediatrics, Japanese Red Cross Narita Hospital, Narita, Japan
,
D Hori
12   Department of Pediatrics and Adolescence, Sapporo Hokuyu Hospital, Sapporo, Japan
,
F Tanaka
13   Department of Pediatrics, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan
,
S Sunami
11   Department of Pediatrics, Japanese Red Cross Narita Hospital, Narita, Japan
,
N Fujita
14   Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan
,
T Mitsui
15   Department of Pediatrics, Yamagata University Hospital, Yamagata, Japan
,
T Mori
16   Department of Pediatrics, St. Marianna University School of Medicine Hospital, Kanagawa, Japan
,
R Kobahashi
12   Department of Pediatrics and Adolescence, Sapporo Hokuyu Hospital, Sapporo, Japan
› Author Affiliations
Further Information

Publication History

Publication Date:
18 March 2020 (online)

Also available at
 

Introduction Pediatric Hodgkin Lymphoma (HL) accounts for approximately 10-20% of lymphoma in pediatric patients, and the incidence of pediatric HL is lower in Japan than in Western countries. Here, we assess a multicenter, single-treatment trial (HL-14) that commenced in 2015 in Japan to determine the risk-adapted omission of radiation therapy for patients with negative fluorodeoxyglucose-positron emission tomography (FDG-PET) results, following an initial treatment response to combination chemotherapy.

Methods Patients with untreated HL aged <20 years at diagnosis are enrolled. The Japanese Pediatric Leukemia/Lymphoma Study Gropup, Japan Children’s Cancer Groupe (JPLSG, JCCG) HL-14 sudy will examine the effects of omitting radiation therapy if the FDG-PET findings after two completed cycles of combination chemotherapy are negative. Low-risk patients (stage IA, IB, and IIA) receive two cycles of OEPA (vincristine, etoposide, prednisolone, and doxorubicin) (boys) or OPPA (vincristine, procarbazine, prednisolone, and doxorubicin) (girls). Intermediate-risk patients (stage IEA, IEB, IIEA, IIB, and IIIA) receive two cycles of OEPA (boys) or OPPA (girls) and two cycles of COPDAC (cyclophosphamide, vincristine, prednisolone, and dacarbazine) (boys) or COPP (cyclophosphamide, vincristine, procarbazine, and prednisolone) (girls). High-risk patients (stage IIEB, IIIEA, IIIEB, IIIB, IVA, and IVB) receive two cycles of OEPA (boys) or OPPA (girls) and four cycles of COPDAC (boys) or COPP (girls). If the PET2 results are negative, no radiation therapy will be administered. All patients with positive PET2 results will receive involved-field, involved-site, or node radiation therapy (20–36 Gy) following the completion of chemotherapy.

Results Our trial is now ongoing.

Conclusion This trial aimed to determine, within the confines of safety, whether assessing treatment response using PET (which is highly sensitive and specific) was effective for Japanese. In our next study, we plan to assess the safety and treatment response of brentuximab vedotin, which is used to treat cases of relapse in Japan, in early induction therapy using evaluation with PET2.

 

  • References

  • 1 Koga Y. et al., The effect of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin’s lymphoma (HL-14): protocol for a phase II study. Acta Med Okayama 2018; 72 ( (04) : 437-440
    PubMedGoogle Scholar
  • 2 Mauz-Korhoz C. , et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: the GPOH-HD-2002 study,. J Clin Oncol 2010; 28 ( (23) : 3680-3686
    CrossrefPubMedGoogle Scholar
  • 3 Kurch L. , et al. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: results of the GPOH-HD2002 trial,. Pediatr Blood Cancer 2019; 66 ( (03) : e27539
    CrossrefPubMedGoogle Scholar